Diabetes drug semaglutide tested in dialysis patients for safety
NCT ID NCT07017270
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether semaglutide, a diabetes drug, is safe and tolerable for people with type 2 diabetes who are on dialysis. About 100 participants will either receive weekly semaglutide injections or standard care for 26 weeks. The goal is to see if patients can stick with the treatment and to gather data for a larger future trial on heart health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide (a GLP-1 receptor agonist, given as a weekly injection)
What this could lead to
If successful, this could show that semaglutide is safe for dialysis patients, potentially leading to better diabetes management and a larger trial on heart outcomes.
What could go wrong
This is a small, early-phase trial focused on safety and feasibility, not effectiveness. Side effects like nausea or low blood sugar may occur, and results may not apply to all dialysis patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Unity Health Toronto
RECRUITINGToronto, Ontario, M5B1W8, Canada
-
Unity Health Toronto
RECRUITINGToronto, Ontario, M5B1W8, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••